NASDAQ: TERN
Terns Pharmaceuticals Inc Stock Ownership - Who owns Terns Pharmaceuticals?

Insider buying vs selling

Have Terns Pharmaceuticals Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Emil KuriakoseChief Medical Officer2025-04-01952$2.49
$2.37kSell
Jill M. QuigleyDirector2025-01-068,760$5.79
$50.76kSell
Mark J. VignolaChief Financial Officer2025-01-069,059$5.80
$52.50kSell
Mark J. VignolaChief Financial Officer2025-01-028,129$5.72
$46.52kSell
Emil KuriakoseChief Medical Officer2025-01-024,481$5.72
$25.61kSell
Jill M. QuigleyDirector2025-01-026,240$5.72
$35.70kSell
Amy L. BurroughsChief Executive Officer2024-12-0515,450$7.15
$110.47kBuy
Amy L. BurroughsChief Executive Officer2024-11-30510$5.11
$2.61kBuy
Melita Sun JungChief Business Officer2024-11-302,250$5.11
$11.50kBuy
Hongbo LuDirector2024-09-12190,476$10.50
$2.00MBuy

1 of 4

TERN insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when TERN insiders and whales buy or sell their stock.

TERN Shareholders

What type of owners hold Terns Pharmaceuticals Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Vivo Opportunity LLC13.21%11,536,701$44.76MInsider
Soleus Capital Management LP9.35%8,167,100$31.69MInstitution
Orbimed Advisors LLC8.66%7,562,971$29.34MInstitution
Morgan Stanley8.14%7,110,105$27.59MInstitution
Vivo Capital LLC7.90%6,895,746$26.76MInstitution
Blackrock Inc6.53%5,706,632$22.14MInstitution
Deep Track Capital LP6.39%5,576,558$21.64MInstitution
Vanguard Group Inc4.75%4,152,156$16.11MInstitution
Citadel Advisors LLC4.47%3,907,887$15.16MInstitution
Schonfeld Strategic Advisors LLC4.40%3,844,867$14.92MInstitution

1 of 3

TERN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
TERN80.38%19.62%Net BuyingNet Selling
ARCT87.83%12.17%Net Selling
CMPX72.73%27.27%Net SellingNet Selling
IVA5.08%0.00%
MBX37.54%62.46%Net BuyingNet Buying

Terns Pharmaceuticals Stock Ownership FAQ

Who owns Terns Pharmaceuticals?

Terns Pharmaceuticals (NASDAQ: TERN) is owned by 95.14% institutional shareholders, 23.22% Terns Pharmaceuticals insiders, and 0.00% retail investors. Vivo Opportunity LLC is the largest individual Terns Pharmaceuticals shareholder, owning 11.54M shares representing 13.21% of the company. Vivo Opportunity LLC's Terns Pharmaceuticals shares are currently valued at $44.76M.

If you're new to stock investing, here's how to buy Terns Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.